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Immune-mediated infl ammatory diseases often 
present with a combination of destructive tis-
sue infl ammation and various systemic mani-
festations. It has been generally believed that 
most such disorders are caused by unregulated 
activation of T helper (Th)1 cells, which pro-
duce the proinfl ammatory cytokines IFN-γ 
and TNF. The success of TNF antagonists for 
treating several of these infl ammatory diseases 
is a striking example of rational immune ther-
apy based on the identifi cation of a key patho-
genic cytokine (1, 2). Recent studies indicate 
that the cytokine IL-17 is the major mediator 
of tissue infl ammation in several models of in-
fl ammatory disease (3–9). These fi ndings have 
led to studies aimed at defi ning the control of 
IL-17 production and its pathologic actions. 
There is also great interest in immunosuppres-
sive approaches targeting the IL-2 pathway and 
in the possible use of regulatory T (T reg) 
 lymphocytes for treating immune-mediated 
 infl ammatory diseases (10–12). To realize this 
potential, it will be necessary to defi ne the 
types of pathological immune reactions that 
can be controlled or reversed by T reg lym-
phocytes. In fact, recent studies have shown 
that T reg lymphocytes do not suppress, and 
may even enhance, IL-17 production by T 
cells, an eff ect that is likely mediated by TGF-β, 
which is produced by T reg lymphocytes and is 
a stimulus for IL-17 production (13–15). Such 
results have raised the possibility that T reg 
lymphocytes may not be useful for immune-
mediated infl ammatory diseases in which IL-17 
plays a central role.
RESULTS AND D I S C U S S I O N 
To address the roles of cytokines and T reg 
lymphocytes in immune-mediated infl amma-
tion, we have established a model in which a 
systemic autoimmune disease is caused by a 
monospecifi c T cell population that can be fol-
lowed quantitatively in vivo. In this model, 
CD4 T cells from the DO11.10 (DO11) T cell 
receptor transgenic mouse, specifi c for the ov-
albumin (OVA)323-339 peptide, are transferred 
into a lymphopenic (Rag−/−) host expressing 
OVA as a secreted, systemic antigen. The trans-
ferred T cells expand, develop into Th1 eff ec-
tor cells, and cause a severe disease characterized 
by weight loss and skin infl ammation (16). The 
disease has many similarities to graft-versus-
host disease (GvHD), in which transferred T 
cells react against host antigens in an environ-
ment defi cient in endogenous lymphocytes. 
Since the signature cytokine of Th1 cells is 
IFN-γ, we fi rst asked if IFN-γ was responsible 
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for the disease. To do this, we compared the pathogenic ef-
fects of wild-type (WT) DO11 cells with those of DO11 cells 
lacking either IFN-γ or the Th1-specifi c transcription factor, 
T-bet (17). Ablating the Th1 response did not ameliorate 
weight loss and, surprisingly, led to more severe infl amma-
tory skin lesions (Fig. 1). The relative severity apparent from 
the external appearance and histology was corroborated by 
scoring the lesions (Fig. 1 B) as described in Materials and 
methods. Cell numbers in lymphoid organs of recipient mice 
that received WT DO11 cells were similar to recipients that 
were transferred with either IFN-γ−/− or T-bet−/− DO11 
cells (unpublished data). IFN-γ has been suggested to play a 
role in the development and/or function of T reg lympho-
cytes (18). To ask if the exacerbated disease in the absence of 
IFN-γ could refl ect a failure of endogenous T reg lympho-
cytes development, we followed the DO11 cells for gene-
ration of CD25+FoxP3+ T reg lymphocytes. These assays 
showed no defect in the numbers of T reg lymphocytes in 
the absence of IFN-γ or T-bet (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20061341/DC1).
We have begun to identify which cell populations  infi ltrate 
the skin in sOVA transgenic (Tg) Rag−/− recipients by isolat-
ing cells from skin and fl ow cytometry. Fig. S2(available at 
http://www.jem.org/cgi/content/full/jem.20061341/DC1) 
shows that the skin is infi ltrated by CD3+KJ1-26+ T cells and 
Gr-1+CD11b+ granulocytes. This is not the case in normal 
naive DO11 Rag−/− mice or normal sOVA Tg Rag−/− mice 
that have not received DO11 cells.
Figure 1. Role of IFN-𝛄 and T-bet in the systemic immune reaction. 
CD4+KJ1-26+CD25− cells were isolated from the lymph nodes and 
spleens of WT, IFN-γ−/−, or T-bet−/− DO11 mice by cell sorting, and 
106 cells were transferred into sOVA Tg Rag−/− mice on day 0. (A) Body 
weight is plotted over time as the percentage of the starting weight 
 before T cell transfer. Data are pooled from six to eight mice per group. 
Alopecia was scored as described in Materials and methods and plotted 
over time. Data are pooled from six to eight mice per group (*, P < 0.05 
 compared with WT DO11 cells). (B) Skin of lower abdomen is shown on 
day 23 after transfer for one representative mouse in each group. H&E 
stain of skin sections is shown on the left, and macroscopic appearance 
of the skin is shown in the middle. Histological scores were obtained as 
described in Materials and methods and averaged from three to four mice 
per group ± SD.
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It is possible that the infl ammatory disease is caused by 
the cytokine IL-17, and production of IL-17 is increased in 
the absence of IFN-γ (19, 20). Because the entire reaction 
in this model involves one T cell population, one can easily 
follow the profi les of cytokines produced by these cells. 
 Intracellular cytokine stains showed that early during the 
course of the disease (5 d after initiation of the reaction), 
there were populations of activated T cells in lymphoid or-
gans that produced either IFN-γ or IL-17 or both cytokines. 
Over time, the IL-17 producers decreased in number (Fig. 
2 A). Strikingly, in the absence of IFN-γ or T-bet, the num-
ber of IL-17– producing T cells did not decline in lymphoid 
organs or in the skin (Fig. 2, B and C). Only very few IL-4–
producing DO11 cells could be found before (day 5–10) or 
after (day 30) development of skin disease (Fig. 2 A). The 
correlation between increased skin infl ammation and IL-17 
production in the absence of a Th1 response suggested 
that the infl ammation was caused primarily by IL-17–
 producing T cells. In fact, an anti–IL-17 antibody was able 
to reduce the skin infl ammation when DO11 T-bet−/− T 
cells were transferred into sOVA Tg Rag−/− recipients, as 
indicated by the severity of alopecia macroscopically and 
microscopically (Fig. 2 D). These results support a reciprocal 
relationship between Th1 responses and IL-17 production 
and indicate that IL-17 is an important cytokine in tissue 
(i.e., skin) infl ammation.
Because of the potential benefi cial eff ect of blocking IL-2 
signaling in immunological reactions, we have been inter-
ested in the types of pathologic immune responses that are 
infl uenced by IL-2. We have previously shown that in the 
absence of IL-2, i.e., when IL-2−/− DO11 cells are trans-
ferred into sOVA Tg Rag−/− IL-2−/− recipients, the mice 
develop a severe, progressive skin disease with massive accu-
mulation of DO11 cells in lymphoid organs and skin. These 
Figure 2. Kinetics and regulation of IL-17 production in systemic 
autoimmunity. (A) 106 purifi ed CD4+ DO11 Rag−/− cells were transferred 
into sOVA Tg Rag−/− mice on day 0. Peripheral lymph nodes were harvested 
at the indicated time points after transfer and stained for intracellular 
 cytokines. All plots are gated on KJ1-26+CD4+ cells. Numbers refer to the 
percentage of cytokine-positive cells. Representative plots are shown 
from one experiment out of four with two to three mice per group. 
(B) CD4+KJ1-26+CD25− cells were isolated from lymph nodes and spleens 
from WT, IFN-γ−/−, or T-bet−/− DO11 mice by cell sorting, and 106 were 
transferred into sOVA Tg Rag−/− mice on day 0. Peripheral lymph nodes 
and skin were harvested on day 10 after transfer, and the percentage of 
KJ1-26+CD4+ cells that express intracellular IFN-γ, IL-17, and IL-4 was 
measured by fl ow cytometric analysis. One representative mouse is shown 
for each group. (C) The percentage of cells producing intracellular IL-17 
was determined as in B at the indicated time points. Each bar represents 
three to four mice from two representative experiments (*, P < 0.05). 
(D) 106 purifi ed CD4+CD25− DO11 T-bet−/− cells were transferred into 
sOVA Tg Rag−/− mice on day 0. The mice were injected with anti–IL-17 or 
control Ig every 3 d. Alopecia was scored on day 16 as described in Materials 
and methods. Data are pooled from three experiments (*, P < 0.05). 
 Macroscopic appearance of the skin of the lower abdomen is shown on day 
18 from one representative mouse in each group. Histological scoring was 
done as described in Materials and methods, and depicted numbers repre-
sent averages of six to seven mice per group ± SD.
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mice fail to recover from the disease and this is associated 
with lack of generation of regulatory T cells (16). To address 
the role of IL-17 in this reaction, we assayed T cells for IL-17 
production in vivo in the absence of IL-2. Surprisingly, large 
numbers of IL-17–producing T cells accumulated in the skin 
in the IL-2–defi cient setting (Fig. 3). In fact, skin infi ltration 
was dominated by IL-17–producing cells, demonstrating that 
effi  cient generation of tissue-infi ltrating IL-17–producing 
cells occurs in the absence of IL-2. Because classical Th1 re-
sponses are dependent on IL-2 (21), our fi ndings raise the 
possibility that IL-17 is an important mediator of the infl am-
matory disease that develops in knockout mice lacking IL-2 
production or signaling (22).
It has been shown recently that T reg lymphocytes pro-
mote IL-17 production in vitro, in the presence of infl amma-
tory cytokines such as IL-6 (13). If this happens in vivo, then 
T reg lymphocytes may not be able to control reactions that 
are dominated by IL-17. To address this directly, we asked if 
OVA-specifi c T reg lymphocytes could prevent the systemic 
infl ammatory syndrome, and how the production of patho-
genic IL-17 is aff ected by the T reg lymphocytes. T reg lym-
phocytes specifi c for a defi ned antigen can be generated 
experimentally by exposing developing CD4 T cells specifi c 
for the antigen to the cognate protein expressed in the thymus. 
We have shown previously that in crosses of DO11 mice 
with RIP-mOVA-transgenics, CD25+FoxP3+ T reg lym-
phocytes develop, because the antigen is expressed in the thymus 
and T cells encounter the antigen during maturation (23). 
CD25highCD4+ DO11 T cells were purifi ed from DO11×RIP-
mOVA Tg mice and cotransferred with WT DO11 cells 
 expressing a diff erent allelic marker (Thy1.1) into lymphope-
nic sOVA Tg recipients. The T reg lymphocytes completely 
prevented the weight loss (Fig. 4 A) and skin infl ammation 
(Fig. 4 B) that are characteristic of the infl ammatory disease. 
Because we were able to distinguish the T reg lymphocytes 
from the eff ector cells, we could determine the eff ects of the 
OVA-specifi c transferred T reg lymphocytes on the response 
patterns of the eff ector T cells of the same specifi city. The 
most striking eff ect of T reg lymphocytes was a profound in-
hibition of T cell accumulation, which was detectable as early 
as 5 d after transfer (Fig. 4 C). T reg lymphocytes almost com-
pletely inhibited the production of IFN-γ but, surprisingly, 
enhanced the frequency of IL-17–producing cells among the 
remaining DO11 cells (Fig. 4 C). However, even though 
the percentage of IL-17–producing cells was increased within 
the surviving eff ector cell population, the total number of 
cytokine -secreting cells was markedly decreased. Importantly, 
when T reg lymphocytes were cotransferred with eff ector 
cells at a lower ratio, there was no longer an increase in the 
percentage of IL-17–producing cells (unpublished data) and 
the total number of IL-17–producing cells was reduced 
(Fig. 4 D). These data indicate that strong immune responses 
to a systemic antigen can be prevented when T reg lympho-
cytes are present at the time of the initial activation, and this 
protective eff ect of T reg lymphocytes is dominant over their 
IL-17–promoting ability. It remains to be determined how 
T reg lymphocytes inhibit the accumulation of eff ector cells. 
A plausible explanation could be competition for IL-2 or 
other growth factors, or, alternatively, T reg lymphocytes 
may inhibit IL-2 production and lead to apoptosis of early 
 activated cells.
Whether or not T reg lymphocytes can also have a pro-
tective eff ect if they are generated or introduced late in the 
course of disease is obviously of clinical relevance. To address 
this question we transferred T reg lymphocytes into sOVA 
Tg Rag−/− recipients 6 d after the transfer of naive DO11 
cells. Pathogenic eff ector cells have accumulated in the mice 
by this time. This late administration of T reg lymphocytes 
did not prevent the systemic disease (unpublished data).
These studies have explored the roles of cytokines and 
T reg lymphocytes in a mouse model of a systemic infl amma-
tory disease. This model resembles systemic GvHD, the com-
mon feature of both being antigen recognition by transferred 
T cells in the context of lymphopenia (24). The strengths 
of the experimental system we have used are that the patho-
logic immune response is quantifi able because it is caused by 
T cells of a single specifi city reacting to their target antigen, 
the disease that develops has both systemic abnormalities and 
local tissue infl ammation, and the disease is controlled by 
endo genously generated T reg lymphocytes. We show that 
the cytokine IL-17 is the mediator of tissue infl ammation in 
this disease (Figs. 1 and 2). Paradoxically, skin infl ammation 
becomes worse in the absence of Th1 cytokines, presumably 
because of a concomitant increase in IL-17 production. 
Worsening of disease in the presence of defective Th1 re-
sponse has also been noted previously in polyclonal models of 
GvHD (25, 26). The cross-regulation of Th1 responses and 
IL-17 has been demonstrated in vitro (19, 20), and our results 
suggest that this is also true in vivo, but the lineage  relationships 
Figure 3. Development of skin-infi ltrating IL-17–producing cells 
in the absence of IL-2. CD4-purifi ed DO11 Rag−/− WT cells were trans-
ferred into sOVA Tg Rag−/− WT mice (WT), or DO11 Rag−/− IL-2−/− cells 
were transferred into sOVA Tg Rag−/− IL-2−/− mice (IL2KO). Ear skin was 
harvested on day 26 after transfer, and cells were isolated as described in 
Materials and methods. (A) The total number of CD4+KJ1-26+ cells recov-
ered from ear skin and (B) the percentage of cytokine-producing KJ1-
26+CD4+IL-17+ cells was determined by intracellular staining. Data are 
pooled from two independent experiments with two to three mice per 
group. (C) The total number of IL-17–producing KJ1-26+ CD4+ cells was 
calculated (*, P < 0.05; **, P < 0.01).
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Figure 4. T reg lymphocytes protect from systemic infl ammatory 
disease but do not suppress IL-17 production. CD4+KJ1-26+CD25− 
cells were purifi ed from lymph nodes and spleens of DO11 WT Thy1.1+ 
mice, and 106 cells were transferred into sOVA Tg Rag−/− mice on 
day 0. CD4+KJ1-26+CD25+ cells were isolated from lymph nodes and 
spleen of DO11×RIP-mOVA Tg mice (Thy1.1−), and 106 cells were co-
transferred in a separate injection on the same day. (A) Body weight is 
plotted over time as the percentage of the starting weight before T cell 
transfer. Data are pooled from four to six mice per group. Alopecia was 
scored as described in Materials and methods (*, P < 0.05 compared 
with recipients that did not receive T reg lymphocytes). (B) H&E stain of 
skin sections is shown on day 23 after transfer from one representative 
mouse in each group. Histological scoring was done as described in 
Materials and methods, and depicted numbers represent averages of 
three to four mice per group ± SD. (C) Cells were harvested from 
 peripheral lymph nodes on day 5 or 9. The total number of isolated 
CD4+KJ1-26+ cells on day 5 and 9 (left), the percentage of cytokine-
producing effector cells by intracellular staining on day 9 (middle), and 
total cell numbers of cytokine-producing effector cells on day 9 (right) 
are shown. All plots are gated on CD4+KJ1-26+Thy1.1+ (*, P < 0.05 
compared with recipients that did not receive T reg lymphocytes). 
(D) 0.3 × 106 CD4+KJ1-26+CD25− cells from DO11 WT Thy1.1+ mice 
were transferred into sOVA Tg Rag−/− mice on day 0, either alone or 
with CD4+KJ1-26+CD25+ from DO11×RIP-mOVA Tg mice (Thy1.1−) 
at a ratio of 1:1 or 1:5 (T reg lymphocytes to effector cells). Cells were 
isolated from peripheral lymph nodes on day 23. The total number of 
isolated CD4+KJ1-26+ cells (left) and the total cell numbers of cytokine-
producing effector cells (right) are shown. All plots are gated on 
CD4+KJ1-26+Thy1.1+ (*, P < 0.05 compared with recipients that did 
not receive T reg lymphocytes).
between Th1 cells and IL-17–producing cells remain to 
be defi ned.
Massive accumulation of IL-17–producing cells in 
 peripheral tissues is independent of IL-2 and also occurs in 
the absence of T reg lymphocytes. In fact, tissue-infi ltrating 
IL-17–producing cells are increased in the absence of IL-2, 
and thus in the absence of T reg lymphocytes. This is empha-
sized by the observation that early after transfer of DO11 
Rag−/− cells, which do not contain T reg lymphocytes and 
at a time point in the disease course when no T reg lympho-
cytes have developed yet (16), strong diff erentiation into 
Th17 has occurred. Our results demonstrate conclusively that 
the development of Th17 cells is, in fact, increased in the ab-
sence of T reg lymphocytes.
Our studies also show that T reg lymphocytes are able to 
completely prevent the infl ammatory disease (13–15, 27). 
The potent disease-preventing eff ect of T reg lymphocytes is 
likely because of the ability of these cells to block initial acti-
vation and, as a consequence, antigen-induced T cell expan-
sion after recognition of the systemic antigen. The inability 
of T reg lymphocytes to ameliorate the disease when given 
late in the course is consistent with the fi nding that the prin-
cipal eff ect of these cells is to inhibit the initial T cell prolif-
eration and generation of pathogenic eff ector cells. This result 
raises the possibility that T reg lymphocytes therapy may be 
of limited benefi t in established immunological diseases. 
However, it is possible that the propagation of such diseases 
is dependent on continuous recruitment of new T cells and 
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their diff erentiation into pathogenic eff ectors. If this is indeed 
the case, T reg lymphocytes may reduce disease severity by 
inhibiting the continued development of eff ector cells from 
newly arising autoreactive precursors. It is also possible that 
T reg lymphocytes may have little eff ect on established in-
fl ammatory lesions that are caused by local IL-17 secretion, 
because T reg lymphocytes do not inhibit, and appear to en-
hance, production of this infl ammatory cytokine. Thus, pro-
tective or pathologic eff ects of infl ammatory cytokines and 
the therapeutic eff ects of T reg lymphocytes vary depending 
on the location, timing, and context.
MATERIALS AND METHODS
Mice. All experimental mice were used at 5–12 wk of age. Mice in each 
 experiment were age and sex matched ±2 wk. BALB/c mice were pur-
chased from Charles River Laboratory. Transgenic mice expressing the 
DO11.10 TCR (DO11), specifi c for the chicken OVA peptide (OVA323–339) 
in the context of the MHC class II molecule I-Ad, were obtained from 
Dr. K. Murphy (Washington University, St. Louis, MO). Some experiments 
were performed using DO11 cells that had been crossed onto a Rag2−/− 
background. For some experiments DO11 Rag2−/− mice were bred onto an 
IL-2−/− background. DO11×RIP-mOVA Tg mice have been described 
(23). DO11 T-bet−/− mice were a gift from Dr. L. Glimcher (Harvard Med-
ical School, Boston, MA), and IFN-γ−/− mice on a BALB/c background 
were obtained from The Jackson Laboratories and crossed with the DO11 
TCR Tg mice. Soluble OVA transgenic mice (sOVA Tg) on a BALB/c 
background, expressing a soluble form of OVA in the serum have been 
 described (28). sOVA Tg mice were bred onto a Rag2−/− background. DO11 
Thy1.1 mice were obtained from Dr. R. Locksley (University of California, 
San Francisco, San Francisco, CA).
Scoring for alopecia was done as follows: <1 cm2 = 1 point, <2 cm2 = 
2 points, >2 cm2 = 3 points, 50% of body surface = 4 points, complete 
 alopecia = 5 points.
All mice were bred and maintained in our pathogen-free facility in ac-
cordance with the guidelines of the Laboratory Animal Resource Center of 
the University of California, San Francisco. All experiments were conducted 
with the approval of the Committee on Animal Research of the University 
of California, San Francisco.
Antibodies and fl ow cytometry. Lymph node cells, splenocytes, and skin 
were stained with the clonotypic antibody KJ1-26 (Caltag Laboratories, 
Burlingame, CA), anti-CD4 (GK1.5, H129.19, and RM4-5), anti-CD25 
(PC61, 7AD), anti-CD62L (MEL-14), anti-Thy1.1 (OX-7), anti-Thy1.2 
(30-H12), anti-CD3 (145-2C11), anti-GR-1 (RB6-8C5), anti-CD11b 
(M1/70), and anti-FoxP3 (FJK-16s; eBioscience). All antibodies were ob-
tained from BD Biosciences unless otherwise stated. Antibodies were used as 
FITC, PE, PE-Cy7, PE-Cy5.5, allophycocyanin, or peridin chlorophyll 
protein conjugates. Fc-block (anti-CD16/CD32) was added before staining. 
Flow cytometric analyses were done on a FACSCalibur with Cellquest Soft-
ware (both from Becton Dickinson). Percentages were rounded after the 
fi rst decimal place. Cells were sorted with a MoFlo cell sorter (Cytomation). 
Propidium iodide (Sigma-Aldrich) was used to exclude dead cells in fl ow 
cytometry of skin samples.
For intracellular cytokine staining, DO11 T cells recovered from periph-
eral lymph nodes, spleen, or skin of transfer recipients were restimulated on 
mitomycin C–treated BALB/c splenocytes for 14 h in the presence of 1 μg/ml 
OVA peptide. Brefeldin A (Epicentre) was added (10 μg/ml) for the last 2 h 
of stimulation. Cells were stained for intracellular cytokines IL-17, IFN-γ, 
IL-4 and analyzed by fl ow cytometry gating on CD4+KJ1-26+ cells.
Anti–IL-17 antibody (M210) was provided by Amgen or obtained from 
R&D Systems (clone 50104). A total of 250 μg (R&D Systems) or 500 μg 
(Amgen) were injected i.p. every 3 d starting on day 4 after transfer. Control 
Rat IgG was obtained from Jackson ImmunoResearch Laboratory.
Statistical analysis was done using two-tailed t test assuming equal 
 variance between the compared groups (**, P < 0.01; *, P < 0.05).
Cell preparations, purifi cations, and adoptive transfer. For isolation 
of T cells from ear skin, the ear was cut off  and split into ventral and dorsal 
half with forceps. The ear halves were minced with a razor blade and incu-
bated at 37°C for 45 min in digestion cocktail containing 0.3% Trypsin from 
bovine pancreas, collagenase XI (4,100 U/ml), hyaluronidase (260 U/ml), 
DNase (0.1 mg/ml) diluted in RPMI, containing 10 mM Hepes and 5% 
FCS (all from Sigma-Aldrich). Digested ears were minced, and isolated cells 
were washed twice with ice-cold medium containing 10 mM EDTA and 
fi ltered through a 40-μm fi lter. Further processing was performed as for cells 
isolated from lymphoid organs.
Histology. Tissues were fi xed in 10% neutral buff ered formalin and embed-
ded in paraffi  n. 5-μm sections were cut and stained with H&E. Sections 
were scored blinded using a histological score for dermal infl ammation 
(grade 1 = less than 15% necrotic cells, infi ltration less than 20% of dermis; 
grade 2 = 15–20% necrotic cells, infi ltration 20–33% of dermis; grade 3 = 
25–50% necrotic cells, infi ltration 33–50% of dermis, grade 4 = necrosis in 
greater than 50% of dermis, infi ltration of more than 50% of dermis) and 
epidermal changes (grade 1 = less than 25% infi ltrating cells, 1–2 cell thick-
ening; grade 2 = 25–50% infi ltrating cells, 3–4 cell thickening; grade 3 = 
50–75% infi ltrating cells, 4–6 cell thickening, grade 4 = 75–100% infi ltrat-
ing cells, more than 6 cell thickening) (29).
Online supplemental material. Fig. S1 demonstrates that peripheral 
FoxP3-expressing T reg lymphocytes develop from naive CD25− WT, 
IFN-γ−/−, and T-bet−/− DO11 cells when transferred into sOVA Tg 
Rag−/−. Fig. S2 shows that the dermatitis of sOVA Tg Rag−/− recipients is 
characterized by accumulation of transferred DO11 T cells and GR-
1+CD11b+ granulocytes in the skin. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20061341/DC1.
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